View Financial HealthFDC 배당 및 자사주 매입배당 기준 점검 3/6FDC 수익으로 충분히 충당되는 현재 수익률 1.22% 보유한 배당금 지급 회사입니다.핵심 정보1.2%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률11.2%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향29%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Nov 15Upcoming dividend of ₹5.00 per shareEligible shareholders must have bought the stock before 22 November 2024. Payment date: 06 December 2024. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 2.0%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.7%).공고 • Feb 10FDC Limited (BSE:531599) announces an Equity Buyback for 2,900,000 shares, representing 1.72% for INR 1,377.5 million.FDC Limited (BSE:531599) announces a share repurchase program. Under the program, the company will repurchase up to 2,900,000 shares, representing 1.72% of its issued share capital for INR 1,377.5 million. The shares will be repurchased at a price of INR 475 per share. The company has fixed February 19, 2022, as the record date. As of February 9, 2022, the company had 168,810,084 shares in issue.모든 업데이트 보기Recent updates공고 • Jul 23FDC Limited to Report Q1, 2027 Results on Aug 05, 2026FDC Limited announced that they will report Q1, 2027 results on Aug 05, 2026Reported Earnings • May 28Full year 2026 earnings released: EPS: ₹17.29 (vs ₹16.39 in FY 2025)Full year 2026 results: EPS: ₹17.29 (up from ₹16.39 in FY 2025). Revenue: ₹22.8b (up 8.4% from FY 2025). Net income: ₹2.81b (up 5.5% from FY 2025). Profit margin: 12% (in line with FY 2025). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • May 27Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹428, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 47% over the past three years.Reported Earnings • Feb 07Third quarter 2026 earnings released: EPS: ₹1.74 (vs ₹2.28 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.74 (down from ₹2.28 in 3Q 2025). Revenue: ₹4.86b (up 4.6% from 3Q 2025). Net income: ₹283.0m (down 24% from 3Q 2025). Profit margin: 5.8% (down from 8.0% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Nov 06Second quarter 2026 earnings releasedSecond quarter 2026 results: Revenue: ₹4.94b (down 3.9% from 2Q 2025). Net income: ₹283.7m (down 61% from 2Q 2025). Profit margin: 5.7% (down from 14% in 2Q 2025). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.공고 • Oct 20+ 1 more updateFDC Limited Announces CFO ChangesFDC Limited informed Mr. Vijay Dharmadatt Bhatt has resigned from the position of Chief Financial Officer (CFO) of the Company in order to pursue better prospects. The Board of Directors, at its meeting held on October 17, 2025, noted and accepted his resignation. Mr. Vijay D. Bhatt will be relieved from the responsibility of CFO after the close of business hours on October 20, 2025. The company further informed that based on the recommendation of the Nomination and Remuneration Committee and the Audit Committee, the Board of Directors of the Company have at its meeting held on October 17, 2025, approved the appointment of Mr. Vishal Shah as the Chief Financial Officer with effect from 24th October, 2025. Mr. Vishal Shah has about 20 years of work experience with an established track record of handling diverse finance portfolios like Business Finance, Costing, Financial Reporting and Treasury in the pharmaceutical industry.공고 • Aug 29+ 2 more updatesFDC Limited to Report Q2, 2026 Results on Nov 05, 2025FDC Limited announced that they will report Q2, 2026 results on Nov 05, 2025공고 • Aug 26FDC Limited, Annual General Meeting, Sep 25, 2025FDC Limited, Annual General Meeting, Sep 25, 2025, at 10:00 Indian Standard Time.New Risk • Aug 08New major risk - Revenue and earnings growthEarnings have declined by 0.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.3% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Reported Earnings • Aug 08First quarter 2026 earnings released: EPS: ₹7.45 (vs ₹7.31 in 1Q 2025)First quarter 2026 results: EPS: ₹7.45 (up from ₹7.31 in 1Q 2025). Revenue: ₹6.84b (up 7.2% from 1Q 2025). Net income: ₹1.21b (up 1.9% from 1Q 2025). Profit margin: 18% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 22% per year.공고 • Aug 02FDC Limited to Report Q1, 2026 Results on Aug 07, 2025FDC Limited announced that they will report Q1, 2026 results on Aug 07, 2025Reported Earnings • May 29Full year 2025 earnings released: EPS: ₹16.39 (vs ₹18.59 in FY 2024)Full year 2025 results: EPS: ₹16.39 (down from ₹18.59 in FY 2024). Revenue: ₹22.0b (up 13% from FY 2024). Net income: ₹2.67b (down 13% from FY 2024). Profit margin: 12% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 22% per year.공고 • May 22FDC Limited to Report Q4, 2025 Results on May 28, 2025FDC Limited announced that they will report Q4, 2025 results on May 28, 2025Reported Earnings • Feb 14Third quarter 2025 earnings released: EPS: ₹2.28 (vs ₹4.86 in 3Q 2024)Third quarter 2025 results: EPS: ₹2.28 (down from ₹4.86 in 3Q 2024). Revenue: ₹4.64b (up 1.3% from 3Q 2024). Net income: ₹370.4m (down 53% from 3Q 2024). Profit margin: 8.0% (down from 17% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Buy Or Sell Opportunity • Feb 10Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.5% to ₹461. The fair value is estimated to be ₹586, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 14%.공고 • Feb 07FDC Limited to Report Q3, 2025 Results on Feb 12, 2025FDC Limited announced that they will report Q3, 2025 results on Feb 12, 2025Buy Or Sell Opportunity • Jan 22Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.7% to ₹466. The fair value is estimated to be ₹586, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 14%.공고 • Dec 19FDC Limited Receives Final Approval from US FDA for the Company's Abbreviated New Drug Application for Cefixime 400 mg TabletsFDC Limited announced that the Company has received final approval from US FDA for the Company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets.Upcoming Dividend • Nov 15Upcoming dividend of ₹5.00 per shareEligible shareholders must have bought the stock before 22 November 2024. Payment date: 06 December 2024. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 2.0%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.7%).Reported Earnings • Nov 07Second quarter 2025 earnings released: EPS: ₹4.43 (vs ₹4.22 in 2Q 2024)Second quarter 2025 results: EPS: ₹4.43 (up from ₹4.22 in 2Q 2024). Revenue: ₹5.49b (up 13% from 2Q 2024). Net income: ₹720.4m (up 3.2% from 2Q 2024). Profit margin: 13% (down from 14% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 18% per year.공고 • Oct 29FDC Limited to Report Q2, 2025 Results on Nov 06, 2024FDC Limited announced that they will report Q2, 2025 results on Nov 06, 2024공고 • Sep 06FDC Limited Announces Cessation of CA Swati Sandesh Mayekar as Non-Independent DirectorFDC Limited announced that CA. Swati Sandesh Mayekar Non-Executive Independent Director of the Company have completed her tenure viz. second term of five (5) consecutive years on September 05, 2024 Consequently, she ceases to be the Independent Director of the company, accordingly she also ceases to be the member of various Board committees with effect from 06 September 2024.공고 • Aug 28FDC Limited, Annual General Meeting, Sep 26, 2024FDC Limited, Annual General Meeting, Sep 26, 2024, at 10:00 Indian Standard Time.Reported Earnings • Aug 08First quarter 2025 earnings released: EPS: ₹7.31 (vs ₹6.62 in 1Q 2024)First quarter 2025 results: EPS: ₹7.31 (up from ₹6.62 in 1Q 2024). Revenue: ₹6.67b (up 24% from 1Q 2024). Net income: ₹1.19b (up 8.3% from 1Q 2024). Profit margin: 18% (down from 21% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 11% per year.공고 • Jul 26FDC Limited to Report Q1, 2025 Results on Aug 07, 2024FDC Limited announced that they will report Q1, 2025 results on Aug 07, 2024Reported Earnings • May 30Full year 2024 earnings released: EPS: ₹18.58 (vs ₹11.67 in FY 2023)Full year 2024 results: EPS: ₹18.58 (up from ₹11.67 in FY 2023). Revenue: ₹20.4b (up 15% from FY 2023). Net income: ₹3.05b (up 57% from FY 2023). Profit margin: 15% (up from 11% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.공고 • May 03FDC Limited Announces Board Completion of Tenure of Independent DirectorsFDC Limited announced that took note of the Completion of tenure of Independent Directors of the Company, namely, Ms. Usha Athreya Chandrasekhar and Mr. Melarkode Ganesan Parameswaran on May 9, 2024.Reported Earnings • Feb 08Third quarter 2024 earnings released: EPS: ₹4.86 (vs ₹2.45 in 3Q 2023)Third quarter 2024 results: EPS: ₹4.86 (up from ₹2.45 in 3Q 2023). Revenue: ₹4.83b (up 18% from 3Q 2023). Net income: ₹792.3m (up 95% from 3Q 2023). Profit margin: 16% (up from 10.0% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.Reported Earnings • Nov 09Second quarter 2024 earnings released: EPS: ₹4.22 (vs ₹3.10 in 2Q 2023)Second quarter 2024 results: EPS: ₹4.22 (up from ₹3.10 in 2Q 2023). Revenue: ₹5.14b (up 15% from 2Q 2023). Net income: ₹698.2m (up 35% from 2Q 2023). Profit margin: 14% (up from 12% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.공고 • Sep 05+ 2 more updatesFDC Limited to Report Fiscal Year 2024 Results on May 29, 2024FDC Limited announced that they will report fiscal year 2024 results on May 29, 2024공고 • Aug 31FDC Limited, Annual General Meeting, Sep 27, 2023FDC Limited, Annual General Meeting, Sep 27, 2023, at 10:00 Indian Standard Time.공고 • Aug 10+ 1 more updateFDC Limited (BSE:531599) agreed to acquire remaining 7% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd. from other existing shareholders.FDC Limited (BSE:531599) agreed to acquire remaining 7% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd. from other existing shareholders on July 13, 2023. The consideration for this transaction will be paid in cash with settlement of their existing outstanding loan with interest. Post completion of this transaction Fair Deal Corporation Pharmaceutical SA (Pty) Ltd will become the wholly owned subsidiary of FDC Limited. Fair Deal Corporation Pharmaceutical SA (Pty) Ltd generated the revenue of ZAR 11.9 million for the year ended March 31, 2023. The transaction has been approved by the Audit Committee and Board of Directors of FDC Limited. The deal is subject to necessary approvals and regulatory compliances.New Risk • Aug 10New major risk - Revenue and earnings growthEarnings have declined by 1.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 10First quarter 2024 earnings released: EPS: ₹6.62 (vs ₹4.23 in 1Q 2023)First quarter 2024 results: EPS: ₹6.62 (up from ₹4.23 in 1Q 2023). Revenue: ₹5.66b (up 14% from 1Q 2023). Net income: ₹1.10b (up 55% from 1Q 2023). Profit margin: 19% (up from 14% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.공고 • Aug 03FDC Limited to Report Q1, 2024 Results on Aug 09, 2023FDC Limited announced that they will report Q1, 2024 results on Aug 09, 2023Reported Earnings • May 30Full year 2023 earnings released: EPS: ₹11.66 (vs ₹12.82 in FY 2022)Full year 2023 results: EPS: ₹11.66 (down from ₹12.82 in FY 2022). Revenue: ₹18.3b (up 20% from FY 2022). Net income: ₹1.94b (down 10% from FY 2022). Profit margin: 11% (down from 14% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Reported Earnings • May 30Full year 2023 earnings released: EPS: ₹11.66 (vs ₹12.82 in FY 2022)Full year 2023 results: EPS: ₹11.66 (down from ₹12.82 in FY 2022). Revenue: ₹18.3b (up 20% from FY 2022). Net income: ₹1.94b (down 10% from FY 2022). Profit margin: 11% (down from 14% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Reported Earnings • Feb 10Third quarter 2023 earnings released: EPS: ₹2.45 (vs ₹2.11 in 3Q 2022)Third quarter 2023 results: EPS: ₹2.45 (up from ₹2.11 in 3Q 2022). Revenue: ₹4.28b (up 25% from 3Q 2022). Net income: ₹407.5m (up 14% from 3Q 2022). Profit margin: 9.5% (in line with 3Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.공고 • Feb 01FDC Limited to Report Q3, 2023 Results on Feb 09, 2023FDC Limited announced that they will report Q3, 2023 results on Feb 09, 2023Reported Earnings • Nov 18Second quarter 2023 earnings released: EPS: ₹3.10 (vs ₹4.28 in 2Q 2022)Second quarter 2023 results: EPS: ₹3.10 (down from ₹4.28 in 2Q 2022). Revenue: ₹4.45b (up 12% from 2Q 2022). Net income: ₹518.4m (down 28% from 2Q 2022). Profit margin: 12% (down from 18% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.Price Target Changed • Nov 16Price target increased to ₹375Up from ₹350, the current price target is provided by 1 analyst. New target price is 32% above last closing price of ₹285. Stock is down 3.4% over the past year. The company is forecast to post earnings per share of ₹20.60 for next year compared to ₹12.82 last year.공고 • Sep 23FDC Limited Approves Appointment of Vijay S. Maniar as an Non-Executive and Independent DirectorFDC Limited announced that the appointment of Mr. Vijay S. Maniar as an non-executive and independent director of the company, with effect from August 4, 2022 till August 3, 2027 has been approved by the shareholders at the 82 Annual General Meeting (`AGM') of the company, held on September 22, 2022, through video conferencing. Education: A Fellow member of the Institute of Chartered Accountants of India (ICAI) having over 35 years of professional experience. Work Experience: ASA & Associates (Top 10 Accounting and Consulting Firm of India) January 2022 – Present: Advisor and Mentor to guide the Mumbai branch operations and teams, including the leadership team to strengthen the practice. S R Batliboi & Co LLP (Indian member firm of EY Global) 1999 – 2021: Engagement partner for statutory audits of large listed as well as unlisted corporates (Indian /multinational /entrepreneurial /PE funded) including those which undertook capital market transactions; Listed corporates include Grasim Industries, Avenue Supermart (DMart), Aditya Birla Fashion and Retail, Shoppers Stop, Huhtamaki Paper Products, Aditya Birla Nuvo, Sanofi, FDC, Excel Industries, Excel Crop Care (now Sumitomo Chemicals), lon Exchange; Sector focused - Retail, Pharma and Chemicals, Packaging, Hospitality, Manufacturing and Real Estate; Extensive audit committee/board meeting experience having attended more than 400 meetings; Special Invitee on Accounting Standards Board (ASB) of ICAI for 2 years; Member of Accounting and Auditing Committee of Bombay Chartered Accountants Society (BCAS) since more than 15 years; Regular speaker at various forums; Co-author of: Guidance Notes on Division |, Il and Ill of Revised Schedule Ill to the Companies Act 2013 issued by ICAI; Guidance Note on Revised Schedule VI to the Companies Act, 1956 issued by ICAI and Mandatory Accounting Standards -- Extracts from Published Accounts issued by BCAS. Maniar & Maniar /Chandrakant Mehta & Associates 1985 – 1999: Set up professional practice and created infrastructure; Engaged with entrepreneurs as a trusted advisor and sounding board; Developed and mentored team to grow with me.공고 • Aug 30+ 2 more updatesFDC Limited to Report Q4, 2023 Results on May 23, 2023FDC Limited announced that they will report Q4, 2023 results on May 23, 2023Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: ₹4.23 (vs ₹5.80 in 1Q 2022)First quarter 2023 results: EPS: ₹4.23 (down from ₹5.80 in 1Q 2022). Revenue: ₹5.14b (up 15% from 1Q 2022). Net income: ₹707.4m (down 28% from 1Q 2022). Profit margin: 14% (down from 22% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.공고 • Jul 22FDC Limited to Report Q1, 2023 Results on Aug 04, 2022FDC Limited announced that they will report Q1, 2023 results on Aug 04, 2022Recent Insider Transactions • Jun 11Board Member recently bought ₹912k worth of stockOn the 8th of June, Melarkode Parameswaran bought around 4k shares on-market at roughly ₹247 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 3 highly experienced directors. Additional Non-Executive & Independent Director Ambi Parameswaran was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • May 27Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₹12.81 (down from ₹17.73 in FY 2021). Net income: ₹2.16b (down 28% from FY 2021). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 27%. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.공고 • May 15FDC Limited to Report Q4, 2022 Results on May 25, 2022FDC Limited announced that they will report Q4, 2022 results on May 25, 2022Price Target Changed • Apr 27Price target decreased to ₹415Down from ₹460, the current price target is provided by 1 analyst. New target price is 52% above last closing price of ₹273. Stock is down 12% over the past year. The company is forecast to post earnings per share of ₹17.60 for next year compared to ₹17.73 last year.공고 • Apr 01Fdc Limited Announces That Nomita R. Chandavarkar Has Stepped Down from the Position of the Executive Director of the Company to Non-Executive Director with Effect from April 01, 2022FDC Limited announced that Ms. Nomita R. Chandavarkar has stepped down from the position of the Executive Director of the Company to Non-Executive Director with effect from April 01, 2022. Therefore she continues to be on the Board of the Company as Non-Executive Non-Independent Director.Reported Earnings • Feb 10Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: ₹2.11 (down from ₹4.45 in 3Q 2021). Revenue: ₹3.55b (up 4.2% from 3Q 2021). Net income: ₹356.9m (down 53% from 3Q 2021). Profit margin: 10% (down from 22% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 9.5%. Earnings per share (EPS) also missed analyst estimates by 7.7%. Over the next year, revenue is forecast to grow 22%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 25% per year.공고 • Feb 10FDC Limited (BSE:531599) announces an Equity Buyback for 2,900,000 shares, representing 1.72% for INR 1,377.5 million.FDC Limited (BSE:531599) announces a share repurchase program. Under the program, the company will repurchase up to 2,900,000 shares, representing 1.72% of its issued share capital for INR 1,377.5 million. The shares will be repurchased at a price of INR 475 per share. The company has fixed February 19, 2022, as the record date. As of February 9, 2022, the company had 168,810,084 shares in issue.Reported Earnings • Nov 16Second quarter 2022 earnings released: EPS ₹4.28 (vs ₹5.15 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹3.98b (up 7.1% from 2Q 2021). Net income: ₹724.0m (down 18% from 2Q 2021). Profit margin: 18% (down from 24% in 2Q 2021). The decrease in margin was driven by higher expenses.Price Target Changed • Nov 16Price target decreased to ₹415Down from ₹470, the current price target is provided by 1 analyst. New target price is 40% above last closing price of ₹297. Stock is down 8.8% over the past year. The company is forecast to post earnings per share of ₹20.80 for next year compared to ₹17.73 last year.Reported Earnings • Aug 18First quarter 2022 earnings released: EPS ₹5.80 (vs ₹5.36 in 1Q 2021)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: ₹4.47b (up 45% from 1Q 2021). Net income: ₹978.7m (up 6.7% from 1Q 2021). Profit margin: 22% (down from 30% in 1Q 2021). The decrease in margin was driven by higher expenses.공고 • Jul 14FDC Limited Launches Favipiravir Oral Suspension -FavenzaFDC Limited announced the launch of India's first oral suspension of Favipiravir - Favenza Oral Suspension, used to treat mild to moderate cases of COVID-19. This prescription-only solution is currently available at all retail medical outlets and hospita pharmacies across the country. The Favenza suspension is unique due to its Convenient Loading Dose (Day 1) of 18 ml in the morning and 18 ml in the evening. The results of which are equivalent to 9 tablets of Favipiravir 400mg making the process of Covid-19 treatment hassle free.Reported Earnings • May 28Full year 2021 earnings released: EPS ₹17.72 (vs ₹13.94 in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2021 results: Revenue: ₹13.3b (flat on FY 2020). Net income: ₹3.01b (up 26% from FY 2020). Profit margin: 23% (up from 18% in FY 2020). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.Price Target Changed • Feb 10Price target raised to ₹470Up from ₹425, the current price target is an average from 2 analysts. The new target price is 69% above the current share price of ₹279. As of last close, the stock is up 11% over the past year.Is New 90 Day High Low • Feb 08New 90-day low: ₹280The company is down 13% from its price of ₹322 on 10 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹156 per share.Reported Earnings • Feb 05Third quarter 2021 earnings released: EPS ₹4.47 (vs ₹4.31 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: ₹3.75b (up 17% from 3Q 2020). Net income: ₹752.5m (up 1.5% from 3Q 2020). Profit margin: 20% (down from 23% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.공고 • Jan 28FDC Limited to Report Q3, 2021 Results on Feb 04, 2021FDC Limited announced that they will report Q3, 2021 results on Feb 04, 2021Is New 90 Day High Low • Jan 21New 90-day low: ₹311The company is down 10.0% from its price of ₹347 on 23 October 2020. The Indian market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹92.93 per share.Reported Earnings • Nov 10Second quarter 2021 earnings released: EPS ₹5.15The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹3.90b (up 13% from 2Q 2020). Net income: ₹880.8m (up 63% from 2Q 2020). Profit margin: 23% (up from 16% in 2Q 2020). The increase in margin was driven by higher revenue.Analyst Estimate Surprise Post Earnings • Nov 10Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Over the next year, revenue is forecast to grow 16%, compared to a 12% growth forecast for the Pharmaceuticals industry in India.Is New 90 Day High Low • Oct 07New 90-day high: ₹368The company is up 50% from its price of ₹245 on 09 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹273 per share.공고 • Sep 12FDC Limited to Report Q1, 2021 Results on Aug 07, 2020FDC Limited announced that they will report Q1, 2021 results on Aug 07, 2020공고 • Aug 08FDC Limited (BSE:531599) entered into definitive agreements to acquire an additional 44% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd from Pharma-Q Holdings Pty for ZAR 0.14 million.FDC Limited (BSE:531599) entered into definitive agreements to acquire an additional 44% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd from Pharma-Q Holdings Pty for ZAR 0.14 million on August 7, 2020. The consideration will be paid in cash for 0.143 million shares. Post acquisition Fair Deal Corporation Pharmaceutical will became a subsidiary of FDC, owning 93% stake. The transaction also involves settlement of outstanding loan of ZAR 6.5 million equivalent to availed by Fair Deal Corporation Pharmaceutical from Pharma Q. For the year ended March 31, 2020, Fair Deal Corporation Pharmaceutical reported revenue of ZAR 2.97 million and loss after tax of ZAR 4.3 million. The said transaction is subject to completion of various closing conditions.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 531599 의 배당금 지급은 지난 10 년 동안 휘발성이었습니다.배당금 증가: 531599 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장FDC 배당 수익률 vs 시장531599의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (531599)1.2%시장 하위 25% (IN)0.3%시장 상위 25% (IN)1.4%업계 평균 (Pharmaceuticals)0.7%분석가 예측 (531599) (최대 3년)n/a주목할만한 배당금: 531599 의 배당금( 1.22% )은 Indian 시장에서 배당금 지급자의 하위 25%( 0.29% )보다 높습니다.고배당: 531599 의 배당금( 1.22% )은 Indian 시장에서 배당금 지급자의 상위 25%( 1.44% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적으로 낮은 지불 비율 ( 28.9% )로 531599 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 586.1% )이 높기 때문에 531599 의 배당금 지급은 현금 흐름으로 잘 충당되지 않습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/25 00:13종가2026/07/24 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스FDC Limited는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullCentrum Broking LimitedKameswari V. S. ChavaliFirstCall Research
Upcoming Dividend • Nov 15Upcoming dividend of ₹5.00 per shareEligible shareholders must have bought the stock before 22 November 2024. Payment date: 06 December 2024. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 2.0%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.7%).
공고 • Feb 10FDC Limited (BSE:531599) announces an Equity Buyback for 2,900,000 shares, representing 1.72% for INR 1,377.5 million.FDC Limited (BSE:531599) announces a share repurchase program. Under the program, the company will repurchase up to 2,900,000 shares, representing 1.72% of its issued share capital for INR 1,377.5 million. The shares will be repurchased at a price of INR 475 per share. The company has fixed February 19, 2022, as the record date. As of February 9, 2022, the company had 168,810,084 shares in issue.
공고 • Jul 23FDC Limited to Report Q1, 2027 Results on Aug 05, 2026FDC Limited announced that they will report Q1, 2027 results on Aug 05, 2026
Reported Earnings • May 28Full year 2026 earnings released: EPS: ₹17.29 (vs ₹16.39 in FY 2025)Full year 2026 results: EPS: ₹17.29 (up from ₹16.39 in FY 2025). Revenue: ₹22.8b (up 8.4% from FY 2025). Net income: ₹2.81b (up 5.5% from FY 2025). Profit margin: 12% (in line with FY 2025). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • May 27Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹428, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 47% over the past three years.
Reported Earnings • Feb 07Third quarter 2026 earnings released: EPS: ₹1.74 (vs ₹2.28 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.74 (down from ₹2.28 in 3Q 2025). Revenue: ₹4.86b (up 4.6% from 3Q 2025). Net income: ₹283.0m (down 24% from 3Q 2025). Profit margin: 5.8% (down from 8.0% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Nov 06Second quarter 2026 earnings releasedSecond quarter 2026 results: Revenue: ₹4.94b (down 3.9% from 2Q 2025). Net income: ₹283.7m (down 61% from 2Q 2025). Profit margin: 5.7% (down from 14% in 2Q 2025). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
공고 • Oct 20+ 1 more updateFDC Limited Announces CFO ChangesFDC Limited informed Mr. Vijay Dharmadatt Bhatt has resigned from the position of Chief Financial Officer (CFO) of the Company in order to pursue better prospects. The Board of Directors, at its meeting held on October 17, 2025, noted and accepted his resignation. Mr. Vijay D. Bhatt will be relieved from the responsibility of CFO after the close of business hours on October 20, 2025. The company further informed that based on the recommendation of the Nomination and Remuneration Committee and the Audit Committee, the Board of Directors of the Company have at its meeting held on October 17, 2025, approved the appointment of Mr. Vishal Shah as the Chief Financial Officer with effect from 24th October, 2025. Mr. Vishal Shah has about 20 years of work experience with an established track record of handling diverse finance portfolios like Business Finance, Costing, Financial Reporting and Treasury in the pharmaceutical industry.
공고 • Aug 29+ 2 more updatesFDC Limited to Report Q2, 2026 Results on Nov 05, 2025FDC Limited announced that they will report Q2, 2026 results on Nov 05, 2025
공고 • Aug 26FDC Limited, Annual General Meeting, Sep 25, 2025FDC Limited, Annual General Meeting, Sep 25, 2025, at 10:00 Indian Standard Time.
New Risk • Aug 08New major risk - Revenue and earnings growthEarnings have declined by 0.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.3% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Reported Earnings • Aug 08First quarter 2026 earnings released: EPS: ₹7.45 (vs ₹7.31 in 1Q 2025)First quarter 2026 results: EPS: ₹7.45 (up from ₹7.31 in 1Q 2025). Revenue: ₹6.84b (up 7.2% from 1Q 2025). Net income: ₹1.21b (up 1.9% from 1Q 2025). Profit margin: 18% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 22% per year.
공고 • Aug 02FDC Limited to Report Q1, 2026 Results on Aug 07, 2025FDC Limited announced that they will report Q1, 2026 results on Aug 07, 2025
Reported Earnings • May 29Full year 2025 earnings released: EPS: ₹16.39 (vs ₹18.59 in FY 2024)Full year 2025 results: EPS: ₹16.39 (down from ₹18.59 in FY 2024). Revenue: ₹22.0b (up 13% from FY 2024). Net income: ₹2.67b (down 13% from FY 2024). Profit margin: 12% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 22% per year.
공고 • May 22FDC Limited to Report Q4, 2025 Results on May 28, 2025FDC Limited announced that they will report Q4, 2025 results on May 28, 2025
Reported Earnings • Feb 14Third quarter 2025 earnings released: EPS: ₹2.28 (vs ₹4.86 in 3Q 2024)Third quarter 2025 results: EPS: ₹2.28 (down from ₹4.86 in 3Q 2024). Revenue: ₹4.64b (up 1.3% from 3Q 2024). Net income: ₹370.4m (down 53% from 3Q 2024). Profit margin: 8.0% (down from 17% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Buy Or Sell Opportunity • Feb 10Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.5% to ₹461. The fair value is estimated to be ₹586, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 14%.
공고 • Feb 07FDC Limited to Report Q3, 2025 Results on Feb 12, 2025FDC Limited announced that they will report Q3, 2025 results on Feb 12, 2025
Buy Or Sell Opportunity • Jan 22Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.7% to ₹466. The fair value is estimated to be ₹586, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 14%.
공고 • Dec 19FDC Limited Receives Final Approval from US FDA for the Company's Abbreviated New Drug Application for Cefixime 400 mg TabletsFDC Limited announced that the Company has received final approval from US FDA for the Company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets.
Upcoming Dividend • Nov 15Upcoming dividend of ₹5.00 per shareEligible shareholders must have bought the stock before 22 November 2024. Payment date: 06 December 2024. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 2.0%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.7%).
Reported Earnings • Nov 07Second quarter 2025 earnings released: EPS: ₹4.43 (vs ₹4.22 in 2Q 2024)Second quarter 2025 results: EPS: ₹4.43 (up from ₹4.22 in 2Q 2024). Revenue: ₹5.49b (up 13% from 2Q 2024). Net income: ₹720.4m (up 3.2% from 2Q 2024). Profit margin: 13% (down from 14% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 18% per year.
공고 • Oct 29FDC Limited to Report Q2, 2025 Results on Nov 06, 2024FDC Limited announced that they will report Q2, 2025 results on Nov 06, 2024
공고 • Sep 06FDC Limited Announces Cessation of CA Swati Sandesh Mayekar as Non-Independent DirectorFDC Limited announced that CA. Swati Sandesh Mayekar Non-Executive Independent Director of the Company have completed her tenure viz. second term of five (5) consecutive years on September 05, 2024 Consequently, she ceases to be the Independent Director of the company, accordingly she also ceases to be the member of various Board committees with effect from 06 September 2024.
공고 • Aug 28FDC Limited, Annual General Meeting, Sep 26, 2024FDC Limited, Annual General Meeting, Sep 26, 2024, at 10:00 Indian Standard Time.
Reported Earnings • Aug 08First quarter 2025 earnings released: EPS: ₹7.31 (vs ₹6.62 in 1Q 2024)First quarter 2025 results: EPS: ₹7.31 (up from ₹6.62 in 1Q 2024). Revenue: ₹6.67b (up 24% from 1Q 2024). Net income: ₹1.19b (up 8.3% from 1Q 2024). Profit margin: 18% (down from 21% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 11% per year.
공고 • Jul 26FDC Limited to Report Q1, 2025 Results on Aug 07, 2024FDC Limited announced that they will report Q1, 2025 results on Aug 07, 2024
Reported Earnings • May 30Full year 2024 earnings released: EPS: ₹18.58 (vs ₹11.67 in FY 2023)Full year 2024 results: EPS: ₹18.58 (up from ₹11.67 in FY 2023). Revenue: ₹20.4b (up 15% from FY 2023). Net income: ₹3.05b (up 57% from FY 2023). Profit margin: 15% (up from 11% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
공고 • May 03FDC Limited Announces Board Completion of Tenure of Independent DirectorsFDC Limited announced that took note of the Completion of tenure of Independent Directors of the Company, namely, Ms. Usha Athreya Chandrasekhar and Mr. Melarkode Ganesan Parameswaran on May 9, 2024.
Reported Earnings • Feb 08Third quarter 2024 earnings released: EPS: ₹4.86 (vs ₹2.45 in 3Q 2023)Third quarter 2024 results: EPS: ₹4.86 (up from ₹2.45 in 3Q 2023). Revenue: ₹4.83b (up 18% from 3Q 2023). Net income: ₹792.3m (up 95% from 3Q 2023). Profit margin: 16% (up from 10.0% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.
Reported Earnings • Nov 09Second quarter 2024 earnings released: EPS: ₹4.22 (vs ₹3.10 in 2Q 2023)Second quarter 2024 results: EPS: ₹4.22 (up from ₹3.10 in 2Q 2023). Revenue: ₹5.14b (up 15% from 2Q 2023). Net income: ₹698.2m (up 35% from 2Q 2023). Profit margin: 14% (up from 12% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
공고 • Sep 05+ 2 more updatesFDC Limited to Report Fiscal Year 2024 Results on May 29, 2024FDC Limited announced that they will report fiscal year 2024 results on May 29, 2024
공고 • Aug 31FDC Limited, Annual General Meeting, Sep 27, 2023FDC Limited, Annual General Meeting, Sep 27, 2023, at 10:00 Indian Standard Time.
공고 • Aug 10+ 1 more updateFDC Limited (BSE:531599) agreed to acquire remaining 7% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd. from other existing shareholders.FDC Limited (BSE:531599) agreed to acquire remaining 7% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd. from other existing shareholders on July 13, 2023. The consideration for this transaction will be paid in cash with settlement of their existing outstanding loan with interest. Post completion of this transaction Fair Deal Corporation Pharmaceutical SA (Pty) Ltd will become the wholly owned subsidiary of FDC Limited. Fair Deal Corporation Pharmaceutical SA (Pty) Ltd generated the revenue of ZAR 11.9 million for the year ended March 31, 2023. The transaction has been approved by the Audit Committee and Board of Directors of FDC Limited. The deal is subject to necessary approvals and regulatory compliances.
New Risk • Aug 10New major risk - Revenue and earnings growthEarnings have declined by 1.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 10First quarter 2024 earnings released: EPS: ₹6.62 (vs ₹4.23 in 1Q 2023)First quarter 2024 results: EPS: ₹6.62 (up from ₹4.23 in 1Q 2023). Revenue: ₹5.66b (up 14% from 1Q 2023). Net income: ₹1.10b (up 55% from 1Q 2023). Profit margin: 19% (up from 14% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
공고 • Aug 03FDC Limited to Report Q1, 2024 Results on Aug 09, 2023FDC Limited announced that they will report Q1, 2024 results on Aug 09, 2023
Reported Earnings • May 30Full year 2023 earnings released: EPS: ₹11.66 (vs ₹12.82 in FY 2022)Full year 2023 results: EPS: ₹11.66 (down from ₹12.82 in FY 2022). Revenue: ₹18.3b (up 20% from FY 2022). Net income: ₹1.94b (down 10% from FY 2022). Profit margin: 11% (down from 14% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Reported Earnings • May 30Full year 2023 earnings released: EPS: ₹11.66 (vs ₹12.82 in FY 2022)Full year 2023 results: EPS: ₹11.66 (down from ₹12.82 in FY 2022). Revenue: ₹18.3b (up 20% from FY 2022). Net income: ₹1.94b (down 10% from FY 2022). Profit margin: 11% (down from 14% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 10Third quarter 2023 earnings released: EPS: ₹2.45 (vs ₹2.11 in 3Q 2022)Third quarter 2023 results: EPS: ₹2.45 (up from ₹2.11 in 3Q 2022). Revenue: ₹4.28b (up 25% from 3Q 2022). Net income: ₹407.5m (up 14% from 3Q 2022). Profit margin: 9.5% (in line with 3Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
공고 • Feb 01FDC Limited to Report Q3, 2023 Results on Feb 09, 2023FDC Limited announced that they will report Q3, 2023 results on Feb 09, 2023
Reported Earnings • Nov 18Second quarter 2023 earnings released: EPS: ₹3.10 (vs ₹4.28 in 2Q 2022)Second quarter 2023 results: EPS: ₹3.10 (down from ₹4.28 in 2Q 2022). Revenue: ₹4.45b (up 12% from 2Q 2022). Net income: ₹518.4m (down 28% from 2Q 2022). Profit margin: 12% (down from 18% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
Price Target Changed • Nov 16Price target increased to ₹375Up from ₹350, the current price target is provided by 1 analyst. New target price is 32% above last closing price of ₹285. Stock is down 3.4% over the past year. The company is forecast to post earnings per share of ₹20.60 for next year compared to ₹12.82 last year.
공고 • Sep 23FDC Limited Approves Appointment of Vijay S. Maniar as an Non-Executive and Independent DirectorFDC Limited announced that the appointment of Mr. Vijay S. Maniar as an non-executive and independent director of the company, with effect from August 4, 2022 till August 3, 2027 has been approved by the shareholders at the 82 Annual General Meeting (`AGM') of the company, held on September 22, 2022, through video conferencing. Education: A Fellow member of the Institute of Chartered Accountants of India (ICAI) having over 35 years of professional experience. Work Experience: ASA & Associates (Top 10 Accounting and Consulting Firm of India) January 2022 – Present: Advisor and Mentor to guide the Mumbai branch operations and teams, including the leadership team to strengthen the practice. S R Batliboi & Co LLP (Indian member firm of EY Global) 1999 – 2021: Engagement partner for statutory audits of large listed as well as unlisted corporates (Indian /multinational /entrepreneurial /PE funded) including those which undertook capital market transactions; Listed corporates include Grasim Industries, Avenue Supermart (DMart), Aditya Birla Fashion and Retail, Shoppers Stop, Huhtamaki Paper Products, Aditya Birla Nuvo, Sanofi, FDC, Excel Industries, Excel Crop Care (now Sumitomo Chemicals), lon Exchange; Sector focused - Retail, Pharma and Chemicals, Packaging, Hospitality, Manufacturing and Real Estate; Extensive audit committee/board meeting experience having attended more than 400 meetings; Special Invitee on Accounting Standards Board (ASB) of ICAI for 2 years; Member of Accounting and Auditing Committee of Bombay Chartered Accountants Society (BCAS) since more than 15 years; Regular speaker at various forums; Co-author of: Guidance Notes on Division |, Il and Ill of Revised Schedule Ill to the Companies Act 2013 issued by ICAI; Guidance Note on Revised Schedule VI to the Companies Act, 1956 issued by ICAI and Mandatory Accounting Standards -- Extracts from Published Accounts issued by BCAS. Maniar & Maniar /Chandrakant Mehta & Associates 1985 – 1999: Set up professional practice and created infrastructure; Engaged with entrepreneurs as a trusted advisor and sounding board; Developed and mentored team to grow with me.
공고 • Aug 30+ 2 more updatesFDC Limited to Report Q4, 2023 Results on May 23, 2023FDC Limited announced that they will report Q4, 2023 results on May 23, 2023
Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: ₹4.23 (vs ₹5.80 in 1Q 2022)First quarter 2023 results: EPS: ₹4.23 (down from ₹5.80 in 1Q 2022). Revenue: ₹5.14b (up 15% from 1Q 2022). Net income: ₹707.4m (down 28% from 1Q 2022). Profit margin: 14% (down from 22% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Jul 22FDC Limited to Report Q1, 2023 Results on Aug 04, 2022FDC Limited announced that they will report Q1, 2023 results on Aug 04, 2022
Recent Insider Transactions • Jun 11Board Member recently bought ₹912k worth of stockOn the 8th of June, Melarkode Parameswaran bought around 4k shares on-market at roughly ₹247 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 3 highly experienced directors. Additional Non-Executive & Independent Director Ambi Parameswaran was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • May 27Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₹12.81 (down from ₹17.73 in FY 2021). Net income: ₹2.16b (down 28% from FY 2021). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 27%. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
공고 • May 15FDC Limited to Report Q4, 2022 Results on May 25, 2022FDC Limited announced that they will report Q4, 2022 results on May 25, 2022
Price Target Changed • Apr 27Price target decreased to ₹415Down from ₹460, the current price target is provided by 1 analyst. New target price is 52% above last closing price of ₹273. Stock is down 12% over the past year. The company is forecast to post earnings per share of ₹17.60 for next year compared to ₹17.73 last year.
공고 • Apr 01Fdc Limited Announces That Nomita R. Chandavarkar Has Stepped Down from the Position of the Executive Director of the Company to Non-Executive Director with Effect from April 01, 2022FDC Limited announced that Ms. Nomita R. Chandavarkar has stepped down from the position of the Executive Director of the Company to Non-Executive Director with effect from April 01, 2022. Therefore she continues to be on the Board of the Company as Non-Executive Non-Independent Director.
Reported Earnings • Feb 10Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: ₹2.11 (down from ₹4.45 in 3Q 2021). Revenue: ₹3.55b (up 4.2% from 3Q 2021). Net income: ₹356.9m (down 53% from 3Q 2021). Profit margin: 10% (down from 22% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 9.5%. Earnings per share (EPS) also missed analyst estimates by 7.7%. Over the next year, revenue is forecast to grow 22%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 25% per year.
공고 • Feb 10FDC Limited (BSE:531599) announces an Equity Buyback for 2,900,000 shares, representing 1.72% for INR 1,377.5 million.FDC Limited (BSE:531599) announces a share repurchase program. Under the program, the company will repurchase up to 2,900,000 shares, representing 1.72% of its issued share capital for INR 1,377.5 million. The shares will be repurchased at a price of INR 475 per share. The company has fixed February 19, 2022, as the record date. As of February 9, 2022, the company had 168,810,084 shares in issue.
Reported Earnings • Nov 16Second quarter 2022 earnings released: EPS ₹4.28 (vs ₹5.15 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹3.98b (up 7.1% from 2Q 2021). Net income: ₹724.0m (down 18% from 2Q 2021). Profit margin: 18% (down from 24% in 2Q 2021). The decrease in margin was driven by higher expenses.
Price Target Changed • Nov 16Price target decreased to ₹415Down from ₹470, the current price target is provided by 1 analyst. New target price is 40% above last closing price of ₹297. Stock is down 8.8% over the past year. The company is forecast to post earnings per share of ₹20.80 for next year compared to ₹17.73 last year.
Reported Earnings • Aug 18First quarter 2022 earnings released: EPS ₹5.80 (vs ₹5.36 in 1Q 2021)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: ₹4.47b (up 45% from 1Q 2021). Net income: ₹978.7m (up 6.7% from 1Q 2021). Profit margin: 22% (down from 30% in 1Q 2021). The decrease in margin was driven by higher expenses.
공고 • Jul 14FDC Limited Launches Favipiravir Oral Suspension -FavenzaFDC Limited announced the launch of India's first oral suspension of Favipiravir - Favenza Oral Suspension, used to treat mild to moderate cases of COVID-19. This prescription-only solution is currently available at all retail medical outlets and hospita pharmacies across the country. The Favenza suspension is unique due to its Convenient Loading Dose (Day 1) of 18 ml in the morning and 18 ml in the evening. The results of which are equivalent to 9 tablets of Favipiravir 400mg making the process of Covid-19 treatment hassle free.
Reported Earnings • May 28Full year 2021 earnings released: EPS ₹17.72 (vs ₹13.94 in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2021 results: Revenue: ₹13.3b (flat on FY 2020). Net income: ₹3.01b (up 26% from FY 2020). Profit margin: 23% (up from 18% in FY 2020). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Feb 10Price target raised to ₹470Up from ₹425, the current price target is an average from 2 analysts. The new target price is 69% above the current share price of ₹279. As of last close, the stock is up 11% over the past year.
Is New 90 Day High Low • Feb 08New 90-day low: ₹280The company is down 13% from its price of ₹322 on 10 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹156 per share.
Reported Earnings • Feb 05Third quarter 2021 earnings released: EPS ₹4.47 (vs ₹4.31 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: ₹3.75b (up 17% from 3Q 2020). Net income: ₹752.5m (up 1.5% from 3Q 2020). Profit margin: 20% (down from 23% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
공고 • Jan 28FDC Limited to Report Q3, 2021 Results on Feb 04, 2021FDC Limited announced that they will report Q3, 2021 results on Feb 04, 2021
Is New 90 Day High Low • Jan 21New 90-day low: ₹311The company is down 10.0% from its price of ₹347 on 23 October 2020. The Indian market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹92.93 per share.
Reported Earnings • Nov 10Second quarter 2021 earnings released: EPS ₹5.15The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹3.90b (up 13% from 2Q 2020). Net income: ₹880.8m (up 63% from 2Q 2020). Profit margin: 23% (up from 16% in 2Q 2020). The increase in margin was driven by higher revenue.
Analyst Estimate Surprise Post Earnings • Nov 10Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Over the next year, revenue is forecast to grow 16%, compared to a 12% growth forecast for the Pharmaceuticals industry in India.
Is New 90 Day High Low • Oct 07New 90-day high: ₹368The company is up 50% from its price of ₹245 on 09 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹273 per share.
공고 • Sep 12FDC Limited to Report Q1, 2021 Results on Aug 07, 2020FDC Limited announced that they will report Q1, 2021 results on Aug 07, 2020
공고 • Aug 08FDC Limited (BSE:531599) entered into definitive agreements to acquire an additional 44% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd from Pharma-Q Holdings Pty for ZAR 0.14 million.FDC Limited (BSE:531599) entered into definitive agreements to acquire an additional 44% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd from Pharma-Q Holdings Pty for ZAR 0.14 million on August 7, 2020. The consideration will be paid in cash for 0.143 million shares. Post acquisition Fair Deal Corporation Pharmaceutical will became a subsidiary of FDC, owning 93% stake. The transaction also involves settlement of outstanding loan of ZAR 6.5 million equivalent to availed by Fair Deal Corporation Pharmaceutical from Pharma Q. For the year ended March 31, 2020, Fair Deal Corporation Pharmaceutical reported revenue of ZAR 2.97 million and loss after tax of ZAR 4.3 million. The said transaction is subject to completion of various closing conditions.